Shigeo Shimose

38PUBLICATIONS
84CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersMedical molecular engineering of nucleic acids and proteins
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (38)

|Feb 24, 2026
Conversion Hepatectomy After New FP Therapy for Malignant Hepatocellular Neoplasm, Not Otherwise Specified: A Case Report.

Etsuko Moriyama, Hironori Koga, Takashi Niizeki

|Feb 06, 2026
Response to 'Reassessing the Clinical Interpretation of Atezolizumab Plus Bevacizumab in Child-Pugh B Hepatocellular Carcinoma'.

Ryu Sasaki, Shigeo Shimose, Issei Saeki

|Nov 28, 2025
Efficacy and Safety of Atezolizumab Plus Bevacizumab for Patients With Hepatocellular Carcinoma and Child-Pugh Class B.

Ryu Sasaki, Shigeo Shimose, Issei Saeki

|Nov 21, 2025
Efficacy and Safety of Lenvatinib Versus Sorafenib in Recurrent HCC After Liver Transplant: A Multi-Center Real-World Study.

Federica Lo Prinzi, Federico Rossari, Antonio De Rosa

|Nov 14, 2025
Outcomes of Sequential Immune Checkpoint Inhibitor Retreatment After Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma.

Takanori Ito, Shigeo Shimose, Issei Saeki

|Nov 03, 2025
Atezolizumab Plus Bevacizumab for TACE-Unsuitable Intermediate-Stage HCC Beyond Up-To-7 Criteria: Final Analysis of REPLACEMENT.

Kazuomi Ueshima, Kaoru Tsuchiya, Tatsuya Yamashita

Pageof 7

Frequent Collaborators

19 joint publications

Takumi Kawaguchi

13 joint publications

Masahito Nakano

12 joint publications

Tomotake Shirono

11 joint publications

Hideki Iwamoto